Sep 30, 2008 by Brian LawlerA Top BioMarin Drug Heads OverseasBioMarin's Kuvan is tentatively given the thumbs up in Europe.
Sep 30, 2008 by Brian LawlerNo Approval for You ... YetThe FDA makes Eli Lilly wait for word on a lead drug.
Sep 30, 2008 by Brian LawlerNovo Nordisk Takes On All ComersIts diabetes franchise is about to get bigger.
Sep 30, 2008 by Brian LawlerMoody's Gets Moody With DrugmakersThe credit rating agency frowns on European pharmaceuticals.
Sep 26, 2008 by Brian LawlerLess Is More for VertexThe company's potential hepatitis C compound proves effective with fewer dosages.
Sep 26, 2008 by Brian LawlerInterMune Previews a Coming AttractionEarly data on its new hepatitis C compound looks good -- for now.
Sep 25, 2008 by Brian LawlerEli Lilly's Dose of DisclosureThe pharmaceutical pledges public reports of its dealings with doctors.
Sep 24, 2008 by Brian LawlerSanofi Gets the Golden RingSanofi-Aventis finally wins a bidding war for a sought-after prize.
Sep 24, 2008 by Brian LawlerBristol-Myers Puts Icahn and ImClone to the TestBristol and Icahn both go hostile toward each other.
Sep 24, 2008 by Brian LawlerOne Share Offering Too Many for Vertex?Vertex raises cash again by diluting itself.
Sep 23, 2008 by Brian LawlerWill Generic Biologics Get Special Treatment?Looking at legislative efforts to boost the biotech industry.
Sep 22, 2008 by Brian LawlerWhy Bristol-Myers Won't Pull Its ImClone Bid Its bid might not be going higher but it isn't going away either.
Sep 19, 2008 by Brian LawlerFDA Tells Gilead to Take 1 More StepThere's a small consolation prize in this rejection from the FDA.
Sep 18, 2008 by Brian LawlerBusy Day for MannKindIt unveils a brand name, a partnership, and new data for its lead drug.
Sep 17, 2008 by Brian LawlerCV Therapeutics Expands Ranexa's ReachA European partner for the developer's angina drug could help rake in sales.
Sep 16, 2008 by Brian LawlerPfizer Puts Safety FirstIncreased FDA scrutiny may motivate the pharmaceutical's new drug-safety site.
Sep 12, 2008 by Brian LawlerKing's Unstoppable Urge to MergeYour potential acquisition isn't interested? Go for the hostile takeover!
Sep 12, 2008 by Brian LawlerA New Wrinkle for an Old DrugAllergan's muscle relaxant Botox performs well in two studies.
Sep 11, 2008 by Brian LawlerWill a Change Cure Sanofi?The drugmaker charts a different course for its future.
Sep 11, 2008 by Brian LawlerImClone and Bristol-Myers' Unfinished BusinessImClone rejects Bristol’s offer, but likely isn’t done dealing with it yet.
